Zynex Announces New Product Development

Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces that its newly formed wholly-owned subsidiary, Zynex Monitoring Solutions Inc., is developing a device for monitoring of central blood volume for use in operating rooms, detecting blood loss during surgery and detecting internal bleeding in the recovery room. A provisional patent has been filed for this unique application, which could serve a currently untapped market of safer surgeries and safer monitoring of patients during recovery.

Thomas Sandgaard, Zynex's CEO, comments: "We already have data confirming the conceptual design and our on-going engineering and prototyping efforts are showing very promising progress. At this early stage, we are also finding that this technology can be used for other applications in cardiac monitoring, and we will continue to explore those options, as stand-alone devices or combined with the blood volume monitoring. We will continue to increase the staff and resources in Monitoring Solutions in order to launch an exciting line of products as soon as possible. We hope to add other complementary technologies, while we initially share some resources with the existing business of electrotherapy products in Zynex Medical, such as clinical research, quality assurance, accounting, purchasing, etc. We are very excited that our initial development effort is showing such positive progress and look forward to further developing a line of products and a strong organization for Monitoring Solutions.”

About Zynex

Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex has also announced the development of two new business units, Zynex Monitoring Solutions and Zynex NeuroDiagnostic.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission, including the "Risk Factors” section of our 10-K Report for the year ended December 31, 2009.